A serological analysis developed by the Institute of Biochemistry and Cell Biology of the CNR and the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome makes it possible to identify the neutralizing antibodies of the SARS-CoV2 virus in environmental samples with low biosafety levels. The technology, which was described in the leading journal Frontiers in Immunology, can also be used in the development of molecules capable of inhibiting viral infection. The technology can be implemented for large-scale screening and can also be used to plan more personalized vaccination strategies.
|